Recombinant Polypeptide Inhibitors Modulating Inflammatory Responses
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively modulate the inflammation response activated by the host's immune system, particularly in addressing the pro-inflammatory activities of proteins like RIPK1, RIPK3, ZBP1, TRIF, CUL1, and NF-κB, which are crucial in viral pathogenesis and autoinflammatory diseases.
Innovation Solution
Development of recombinant polypeptide inhibitors with Ankyrin repeat motifs that exhibit high sequence identity with specific viral proteins, targeting RIPK1, RIPK3, TRIF, ZBP1, CUL1, and SKP1 to modulate immune responses, thereby treating inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods are used to modulate inflammation response, then the treatment approach is simple, but the effectiveness is insufficient for addressing pro-inflammatory activities of proteins like RIPK1, RIPK3, ZBP1, TRIF, CUL1, and NF-κB
Solution Approach 1:
The patent employs composite material principles by formulating therapeutic compositions that combine multiple inhibitory agents or compounds with different mechanisms of action targeting various pro-inflammatory proteins (RIPK1, RIPK3, ZBP1, TRIF, CUL1, NF-κB). This multi-component approach enhances the reliability and effectiveness of inflammation modulation while managing the inherent complexity through systematic formulation design.
2Productivity
If viral inhibitors are used to block necroptosis, then viral replication is facilitated, but anti-viral inflammation is reduced
Solution Approach 1:
The patent applies parameter changes by using small molecule inhibitors that specifically modulate the activity of necroptosis-related proteins (RIPK1, RIPK3, MLKL) to alter the cellular response parameters. By controlling the degree of necroptosis inhibition rather than complete blockade, the therapy achieves a balance between facilitating viral clearance and maintaining protective anti-viral inflammation, thus managing the harmful effects while preserving beneficial immune responses.
3Object-generated harmful factors
If caspase 8 is inhibited to induce necroptosis, then anti-viral inflammation is enhanced, but viral pathogens can evade this response
Solution Approach 1:
The patent introduces intermediary compounds that act as modulators between the caspase 8 inhibition pathway and the necroptosis execution machinery. These small molecule inhibitors target intermediate proteins in the necroptosis pathway (RIPK1, RIPK3, MLKL) to fine-tune the inflammatory response, preventing viral pathogens from completely evading the anti-viral defense while avoiding excessive inflammation that could be detrimental to the host.
Data Source
AI summary
The present disclosure provides compositions and methods related to the modulation of the inflammation response activated by a host's immune system. In particular, the present disclosure provides novel inhibitors of proteins that exhibit pro-inflammatory activity (e.g., RIPK1, RIPK3, ZBP1, TRIF, CUL1, SKP1, and NF-κB, among others), as well as corresponding therapeutic compositions and methods of treatment using these inhibitors.